| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 96 | 2024 | 2671 | 6.080 |
Why?
|
| Cardiovascular Diseases | 149 | 2024 | 15649 | 3.820 |
Why?
|
| Antioxidants | 45 | 2020 | 1673 | 3.130 |
Why?
|
| Aspirin | 53 | 2024 | 3135 | 2.930 |
Why?
|
| Vitamin E | 31 | 2022 | 874 | 2.630 |
Why?
|
| Vitamins | 27 | 2022 | 1637 | 2.610 |
Why?
|
| beta Carotene | 51 | 2018 | 523 | 2.490 |
Why?
|
| Genome-Wide Association Study | 85 | 2025 | 12778 | 2.310 |
Why?
|
| Physicians | 81 | 2022 | 4614 | 2.270 |
Why?
|
| Heart Failure | 58 | 2025 | 11858 | 2.200 |
Why?
|
| Alcohol Drinking | 46 | 2024 | 4049 | 2.180 |
Why?
|
| Ascorbic Acid | 18 | 2022 | 658 | 2.110 |
Why?
|
| Hypertension | 60 | 2024 | 8615 | 2.060 |
Why?
|
| Dietary Supplements | 36 | 2022 | 3443 | 2.010 |
Why?
|
| Risk Factors | 313 | 2025 | 74962 | 1.940 |
Why?
|
| Cholesterol, HDL | 23 | 2024 | 1820 | 1.850 |
Why?
|
| Diet | 55 | 2024 | 8090 | 1.730 |
Why?
|
| Aged | 412 | 2025 | 171562 | 1.720 |
Why?
|
| Myocardial Infarction | 65 | 2024 | 11516 | 1.660 |
Why?
|
| Polymorphism, Single Nucleotide | 93 | 2025 | 16028 | 1.600 |
Why?
|
| Middle Aged | 447 | 2025 | 223491 | 1.590 |
Why?
|
| Eggs | 7 | 2022 | 182 | 1.580 |
Why?
|
| Carotenoids | 24 | 2008 | 620 | 1.580 |
Why?
|
| Coronary Disease | 27 | 2023 | 5924 | 1.500 |
Why?
|
| Cholesterol | 26 | 2023 | 2912 | 1.470 |
Why?
|
| Genetic Predisposition to Disease | 85 | 2025 | 18048 | 1.470 |
Why?
|
| Body Mass Index | 62 | 2024 | 13052 | 1.460 |
Why?
|
| Male | 499 | 2025 | 364902 | 1.460 |
Why?
|
| Prospective Studies | 201 | 2024 | 54920 | 1.450 |
Why?
|
| Blood Pressure | 38 | 2024 | 8541 | 1.350 |
Why?
|
| Proportional Hazards Models | 95 | 2024 | 12558 | 1.350 |
Why?
|
| Humans | 695 | 2025 | 768393 | 1.330 |
Why?
|
| Prostatic Neoplasms | 55 | 2024 | 11221 | 1.310 |
Why?
|
| United States Department of Veterans Affairs | 28 | 2024 | 940 | 1.310 |
Why?
|
| Bromocriptine | 4 | 2015 | 93 | 1.290 |
Why?
|
| United States | 208 | 2025 | 73150 | 1.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 43 | 2024 | 12241 | 1.270 |
Why?
|
| Coronary Artery Disease | 30 | 2025 | 6567 | 1.240 |
Why?
|
| Fatty Acids, Monounsaturated | 8 | 2020 | 190 | 1.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 20 | 2024 | 2276 | 1.230 |
Why?
|
| Nuts | 9 | 2021 | 264 | 1.220 |
Why?
|
| Pancreatic Neoplasms | 32 | 2024 | 5443 | 1.210 |
Why?
|
| Case-Control Studies | 123 | 2024 | 22296 | 1.210 |
Why?
|
| Stroke | 46 | 2024 | 9742 | 1.190 |
Why?
|
| Cholesterol, LDL | 20 | 2025 | 2398 | 1.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 16 | 2023 | 3252 | 1.180 |
Why?
|
| Macular Degeneration | 8 | 2024 | 1016 | 1.170 |
Why?
|
| Cohort Studies | 140 | 2024 | 41795 | 1.160 |
Why?
|
| Aged, 80 and over | 165 | 2024 | 59686 | 1.140 |
Why?
|
| Incidence | 96 | 2024 | 21544 | 1.130 |
Why?
|
| Follow-Up Studies | 120 | 2021 | 39407 | 1.110 |
Why?
|
| Randomized Controlled Trials as Topic | 76 | 2020 | 10377 | 1.110 |
Why?
|
| Risk Assessment | 86 | 2025 | 24318 | 1.090 |
Why?
|
| Veterans Health | 7 | 2021 | 215 | 1.080 |
Why?
|
| Double-Blind Method | 70 | 2022 | 12456 | 1.050 |
Why?
|
| Risk | 63 | 2021 | 9636 | 1.040 |
Why?
|
| Lipids | 22 | 2024 | 3344 | 0.980 |
Why?
|
| Homocysteine | 12 | 2017 | 637 | 0.980 |
Why?
|
| Life Style | 33 | 2023 | 3929 | 0.960 |
Why?
|
| Smoking | 48 | 2024 | 9111 | 0.960 |
Why?
|
| Mendelian Randomization Analysis | 13 | 2024 | 1037 | 0.960 |
Why?
|
| Platelet Aggregation Inhibitors | 11 | 2018 | 2763 | 0.940 |
Why?
|
| Fatty Acids, Omega-3 | 11 | 2023 | 1398 | 0.940 |
Why?
|
| Female | 333 | 2025 | 397089 | 0.870 |
Why?
|
| Anticarcinogenic Agents | 7 | 2017 | 251 | 0.850 |
Why?
|
| Primary Prevention | 9 | 2019 | 1187 | 0.840 |
Why?
|
| Cholesterol, Dietary | 8 | 2010 | 224 | 0.820 |
Why?
|
| Oleic Acids | 2 | 2013 | 72 | 0.820 |
Why?
|
| Phospholipids | 6 | 2017 | 783 | 0.790 |
Why?
|
| Cardiology | 7 | 2021 | 1701 | 0.780 |
Why?
|
| Analgesics, Non-Narcotic | 4 | 2006 | 371 | 0.760 |
Why?
|
| Multivariate Analysis | 50 | 2021 | 12092 | 0.740 |
Why?
|
| Dopamine Agonists | 3 | 2015 | 353 | 0.730 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 141 | 0.720 |
Why?
|
| Adult | 215 | 2024 | 223640 | 0.720 |
Why?
|
| Cataract | 6 | 2015 | 837 | 0.700 |
Why?
|
| Neoplasms | 46 | 2024 | 22385 | 0.690 |
Why?
|
| Odds Ratio | 42 | 2021 | 9682 | 0.680 |
Why?
|
| Hypercholesterolemia | 14 | 2018 | 1142 | 0.680 |
Why?
|
| Electronic Health Records | 19 | 2025 | 4875 | 0.680 |
Why?
|
| Risk Reduction Behavior | 8 | 2019 | 1118 | 0.680 |
Why?
|
| Immunization, Passive | 1 | 2021 | 619 | 0.640 |
Why?
|
| Dyslipidemias | 4 | 2012 | 873 | 0.630 |
Why?
|
| Solanum tuberosum | 3 | 2024 | 47 | 0.620 |
Why?
|
| Aging | 15 | 2022 | 8764 | 0.620 |
Why?
|
| Military Personnel | 5 | 2024 | 1266 | 0.610 |
Why?
|
| C-Reactive Protein | 16 | 2023 | 3857 | 0.600 |
Why?
|
| Fatty Acids, Unsaturated | 5 | 2020 | 542 | 0.600 |
Why?
|
| Cholangiocarcinoma | 6 | 2020 | 562 | 0.600 |
Why?
|
| Plasma | 1 | 2021 | 585 | 0.600 |
Why?
|
| Bile Duct Neoplasms | 6 | 2019 | 616 | 0.600 |
Why?
|
| Confidence Intervals | 20 | 2019 | 2931 | 0.590 |
Why?
|
| Folic Acid | 12 | 2018 | 1336 | 0.590 |
Why?
|
| Genotype | 46 | 2023 | 13042 | 0.580 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2020 | 708 | 0.580 |
Why?
|
| Warfarin | 2 | 2016 | 1493 | 0.580 |
Why?
|
| Vitamin B 6 | 6 | 2019 | 234 | 0.580 |
Why?
|
| Anticholesteremic Agents | 8 | 2013 | 972 | 0.580 |
Why?
|
| Hyperlipidemias | 7 | 2018 | 773 | 0.580 |
Why?
|
| Selenium | 9 | 2020 | 418 | 0.570 |
Why?
|
| Quantitative Trait Loci | 9 | 2024 | 2127 | 0.560 |
Why?
|
| Logistic Models | 39 | 2018 | 13323 | 0.560 |
Why?
|
| Seafood | 4 | 2019 | 395 | 0.560 |
Why?
|
| Vitamin D | 11 | 2024 | 3310 | 0.560 |
Why?
|
| Biological Specimen Banks | 4 | 2024 | 784 | 0.560 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2023 | 2296 | 0.560 |
Why?
|
| Glomerular Filtration Rate | 16 | 2024 | 2226 | 0.550 |
Why?
|
| Obesity | 28 | 2023 | 13084 | 0.550 |
Why?
|
| Atrial Fibrillation | 12 | 2023 | 5168 | 0.530 |
Why?
|
| Cardiac Output, Low | 2 | 2007 | 191 | 0.530 |
Why?
|
| Diabetes Mellitus | 18 | 2023 | 5891 | 0.530 |
Why?
|
| Motor Activity | 8 | 2015 | 2720 | 0.530 |
Why?
|
| Exercise | 17 | 2024 | 5946 | 0.520 |
Why?
|
| Cacao | 5 | 2015 | 98 | 0.510 |
Why?
|
| Cause of Death | 23 | 2024 | 3728 | 0.510 |
Why?
|
| Galectin 3 | 2 | 2016 | 240 | 0.510 |
Why?
|
| Plaque, Atherosclerotic | 7 | 2025 | 1548 | 0.500 |
Why?
|
| Self Report | 16 | 2024 | 3766 | 0.500 |
Why?
|
| Triglycerides | 12 | 2013 | 2465 | 0.500 |
Why?
|
| Overweight | 11 | 2015 | 2445 | 0.490 |
Why?
|
| Health Status | 12 | 2024 | 4094 | 0.490 |
Why?
|
| Aminoacyltransferases | 1 | 2015 | 52 | 0.490 |
Why?
|
| Dietary Fats | 9 | 2023 | 2003 | 0.490 |
Why?
|
| Kidney Diseases | 7 | 2011 | 2103 | 0.480 |
Why?
|
| Health Behavior | 9 | 2015 | 2647 | 0.480 |
Why?
|
| alpha-Tocopherol | 8 | 2017 | 126 | 0.480 |
Why?
|
| Antihypertensive Agents | 7 | 2021 | 2027 | 0.470 |
Why?
|
| Coffee | 5 | 2020 | 598 | 0.470 |
Why?
|
| alpha-Linolenic Acid | 2 | 2014 | 144 | 0.450 |
Why?
|
| Forecasting | 4 | 2018 | 2948 | 0.440 |
Why?
|
| Cholesterol, VLDL | 1 | 2013 | 70 | 0.440 |
Why?
|
| Kidney | 13 | 2023 | 7064 | 0.440 |
Why?
|
| Persian Gulf Syndrome | 2 | 2024 | 48 | 0.430 |
Why?
|
| Atherosclerosis | 7 | 2024 | 3431 | 0.430 |
Why?
|
| Men's Health | 3 | 2017 | 75 | 0.430 |
Why?
|
| Apolipoprotein E4 | 4 | 2024 | 711 | 0.430 |
Why?
|
| Intracranial Hemorrhages | 3 | 2016 | 811 | 0.420 |
Why?
|
| Kynurenine | 4 | 2023 | 142 | 0.420 |
Why?
|
| Adiponectin | 3 | 2013 | 1117 | 0.410 |
Why?
|
| Mortality | 13 | 2023 | 2917 | 0.410 |
Why?
|
| Diabetes Complications | 11 | 2020 | 1322 | 0.410 |
Why?
|
| Gulf War | 4 | 2024 | 33 | 0.410 |
Why?
|
| Eating | 4 | 2012 | 1541 | 0.410 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 9 | 2014 | 415 | 0.410 |
Why?
|
| Hormone Antagonists | 1 | 2012 | 107 | 0.410 |
Why?
|
| Vitamin B Complex | 6 | 2017 | 299 | 0.400 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 344 | 0.400 |
Why?
|
| Hyperglycemia | 4 | 2015 | 1389 | 0.400 |
Why?
|
| Liver Neoplasms | 8 | 2020 | 4365 | 0.400 |
Why?
|
| Fishes | 6 | 2019 | 606 | 0.400 |
Why?
|
| Frail Elderly | 7 | 2024 | 775 | 0.390 |
Why?
|
| Cardiomyopathies | 3 | 2023 | 2056 | 0.390 |
Why?
|
| Marijuana Abuse | 2 | 2023 | 410 | 0.390 |
Why?
|
| Genetic Loci | 10 | 2024 | 2630 | 0.380 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2023 | 563 | 0.380 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 2024 | 4641 | 0.370 |
Why?
|
| Vitamin A | 5 | 2017 | 611 | 0.370 |
Why?
|
| Polymorphism, Genetic | 15 | 2022 | 4250 | 0.370 |
Why?
|
| Fatty Acids, Omega-6 | 3 | 2020 | 225 | 0.360 |
Why?
|
| Acetaminophen | 6 | 2022 | 556 | 0.360 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 438 | 0.360 |
Why?
|
| Chromosomes, Human, X | 3 | 2024 | 320 | 0.360 |
Why?
|
| Carbon | 4 | 2021 | 672 | 0.350 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 1890 | 0.350 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 5 | 2023 | 325 | 0.350 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 294 | 0.350 |
Why?
|
| Biomedical Technology | 1 | 2012 | 210 | 0.350 |
Why?
|
| Carcinoma, Large Cell | 3 | 2019 | 114 | 0.350 |
Why?
|
| Deglutition Disorders | 6 | 2016 | 641 | 0.340 |
Why?
|
| Lipoproteins, LDL | 6 | 2011 | 643 | 0.340 |
Why?
|
| Genetic Association Studies | 12 | 2024 | 2742 | 0.340 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2012 | 487 | 0.340 |
Why?
|
| Comorbidity | 23 | 2022 | 10588 | 0.340 |
Why?
|
| Cystatins | 2 | 2021 | 55 | 0.340 |
Why?
|
| Inflammation | 12 | 2024 | 10863 | 0.340 |
Why?
|
| Hospitalization | 15 | 2025 | 10844 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 9 | 2014 | 1943 | 0.340 |
Why?
|
| Cognition Disorders | 7 | 2019 | 3985 | 0.340 |
Why?
|
| Influenza, Human | 4 | 2022 | 1539 | 0.330 |
Why?
|
| Genetic Variation | 14 | 2025 | 6606 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 5 | 4 | 2016 | 387 | 0.330 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2012 | 361 | 0.330 |
Why?
|
| Feeding Behavior | 12 | 2014 | 3203 | 0.330 |
Why?
|
| Brain Ischemia | 11 | 2011 | 3008 | 0.330 |
Why?
|
| Cicatrix | 1 | 2015 | 799 | 0.330 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 3707 | 0.320 |
Why?
|
| Fasting | 5 | 2012 | 1610 | 0.320 |
Why?
|
| Trans Fatty Acids | 3 | 2023 | 155 | 0.320 |
Why?
|
| Lovastatin | 3 | 2011 | 115 | 0.320 |
Why?
|
| Venous Thromboembolism | 4 | 2023 | 1881 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 7 | 2024 | 2491 | 0.320 |
Why?
|
| Influenza Vaccines | 3 | 2022 | 780 | 0.320 |
Why?
|
| Cognition | 8 | 2019 | 7075 | 0.320 |
Why?
|
| Meat | 4 | 2024 | 588 | 0.310 |
Why?
|
| Docosahexaenoic Acids | 2 | 2023 | 907 | 0.310 |
Why?
|
| Medication Adherence | 3 | 2020 | 2189 | 0.310 |
Why?
|
| Epidemiology | 2 | 2010 | 279 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2020 | 2336 | 0.310 |
Why?
|
| Adenocarcinoma | 10 | 2021 | 6406 | 0.300 |
Why?
|
| Alzheimer Disease | 5 | 2024 | 8747 | 0.300 |
Why?
|
| Physical Fitness | 3 | 2019 | 744 | 0.300 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 13576 | 0.300 |
Why?
|
| Fruit | 7 | 2017 | 1164 | 0.300 |
Why?
|
| Vegetables | 7 | 2017 | 1198 | 0.300 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2024 | 407 | 0.300 |
Why?
|
| Pyrroles | 2 | 2011 | 1126 | 0.300 |
Why?
|
| Phenotype | 20 | 2025 | 16721 | 0.290 |
Why?
|
| Time Factors | 32 | 2021 | 40272 | 0.290 |
Why?
|
| Epidemiologic Studies | 2 | 2010 | 678 | 0.290 |
Why?
|
| Algorithms | 13 | 2025 | 14154 | 0.290 |
Why?
|
| Research Design | 12 | 2018 | 6210 | 0.290 |
Why?
|
| Treatment Outcome | 36 | 2022 | 65379 | 0.290 |
Why?
|
| Alcoholism | 4 | 2023 | 1982 | 0.290 |
Why?
|
| Renal Insufficiency | 2 | 2005 | 809 | 0.290 |
Why?
|
| Diet, Mediterranean | 3 | 2021 | 744 | 0.280 |
Why?
|
| Pravastatin | 3 | 2011 | 393 | 0.280 |
Why?
|
| Linear Models | 8 | 2019 | 5878 | 0.280 |
Why?
|
| Dementia | 3 | 2024 | 2729 | 0.280 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 417 | 0.280 |
Why?
|
| Mosaicism | 3 | 2016 | 481 | 0.280 |
Why?
|
| Health Surveys | 10 | 2024 | 4056 | 0.280 |
Why?
|
| International Classification of Diseases | 3 | 2021 | 924 | 0.270 |
Why?
|
| Women's Health | 8 | 2021 | 2078 | 0.270 |
Why?
|
| Multiple Myeloma | 5 | 2024 | 5192 | 0.270 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2020 | 554 | 0.270 |
Why?
|
| Longitudinal Studies | 16 | 2024 | 14784 | 0.270 |
Why?
|
| C-Peptide | 5 | 2012 | 443 | 0.270 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 609 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 4 | 2021 | 1303 | 0.270 |
Why?
|
| Vascular Diseases | 5 | 2019 | 1161 | 0.270 |
Why?
|
| Retrospective Studies | 41 | 2024 | 81801 | 0.270 |
Why?
|
| Creatinine | 8 | 2022 | 1915 | 0.260 |
Why?
|
| Interleukin-6 | 5 | 2015 | 3230 | 0.260 |
Why?
|
| Stroke Volume | 9 | 2024 | 5619 | 0.260 |
Why?
|
| Coronary Vessels | 7 | 2023 | 3125 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2022 | 2144 | 0.260 |
Why?
|
| Glioma | 7 | 2015 | 3526 | 0.260 |
Why?
|
| Alcoholic Beverages | 4 | 2023 | 266 | 0.260 |
Why?
|
| Genomics | 5 | 2022 | 5916 | 0.250 |
Why?
|
| Bipolar Disorder | 5 | 2024 | 5126 | 0.250 |
Why?
|
| Restless Legs Syndrome | 3 | 2013 | 235 | 0.250 |
Why?
|
| Diet Surveys | 6 | 2014 | 1160 | 0.250 |
Why?
|
| Age Factors | 23 | 2022 | 18471 | 0.250 |
Why?
|
| Cooking | 2 | 2019 | 312 | 0.250 |
Why?
|
| Anthropometry | 4 | 2019 | 1343 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 3722 | 0.240 |
Why?
|
| Blood Glucose | 8 | 2019 | 6430 | 0.240 |
Why?
|
| Candy | 2 | 2014 | 36 | 0.240 |
Why?
|
| Body Height | 5 | 2018 | 1568 | 0.240 |
Why?
|
| Ethanol | 4 | 2014 | 1332 | 0.240 |
Why?
|
| Food Analysis | 1 | 2005 | 103 | 0.240 |
Why?
|
| Cross-Sectional Studies | 28 | 2024 | 26375 | 0.240 |
Why?
|
| Prognosis | 28 | 2019 | 30022 | 0.240 |
Why?
|
| ABO Blood-Group System | 4 | 2013 | 381 | 0.240 |
Why?
|
| Visual Acuity | 6 | 2017 | 2714 | 0.240 |
Why?
|
| Erythrocytes | 4 | 2015 | 2421 | 0.230 |
Why?
|
| Marijuana Smoking | 1 | 2008 | 259 | 0.230 |
Why?
|
| Awareness | 1 | 2009 | 653 | 0.230 |
Why?
|
| Natural Language Processing | 3 | 2024 | 1202 | 0.230 |
Why?
|
| Europe | 11 | 2021 | 3439 | 0.230 |
Why?
|
| Tocopherols | 3 | 2014 | 44 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2021 | 1755 | 0.230 |
Why?
|
| Family Health | 2 | 2008 | 1255 | 0.230 |
Why?
|
| Sex Factors | 15 | 2024 | 10654 | 0.230 |
Why?
|
| Prevalence | 19 | 2021 | 15872 | 0.230 |
Why?
|
| Heart Diseases | 2 | 2018 | 2819 | 0.230 |
Why?
|
| Schizophrenia | 5 | 2024 | 6987 | 0.230 |
Why?
|
| Vietnam Conflict | 1 | 2024 | 101 | 0.230 |
Why?
|
| Lipoproteins, HDL | 4 | 2011 | 682 | 0.230 |
Why?
|
| Epiretinal Membrane | 1 | 2024 | 73 | 0.220 |
Why?
|
| Waist Circumference | 6 | 2019 | 935 | 0.220 |
Why?
|
| Gout | 2 | 2022 | 621 | 0.220 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2020 | 304 | 0.220 |
Why?
|
| Self Disclosure | 1 | 2005 | 249 | 0.220 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 445 | 0.220 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 646 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 450 | 0.220 |
Why?
|
| Geriatric Assessment | 5 | 2024 | 1422 | 0.220 |
Why?
|
| Survival Rate | 14 | 2018 | 12870 | 0.220 |
Why?
|
| Severity of Illness Index | 11 | 2025 | 15939 | 0.220 |
Why?
|
| Cotinine | 3 | 2018 | 206 | 0.220 |
Why?
|
| Saphenous Vein | 2 | 2018 | 519 | 0.220 |
Why?
|
| Dietary Fats, Unsaturated | 3 | 2020 | 223 | 0.210 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2018 | 374 | 0.210 |
Why?
|
| Sodium | 2 | 2019 | 1594 | 0.210 |
Why?
|
| Coronary Artery Bypass | 5 | 2019 | 2194 | 0.210 |
Why?
|
| Arteriosclerosis | 5 | 2000 | 1056 | 0.210 |
Why?
|
| Vitamin B 12 | 5 | 2008 | 527 | 0.210 |
Why?
|
| Epidemiologic Research Design | 2 | 2018 | 368 | 0.210 |
Why?
|
| Bradycardia | 1 | 2025 | 305 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 5 | 2012 | 7453 | 0.210 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 544 | 0.210 |
Why?
|
| Chronic Disease | 14 | 2020 | 9379 | 0.210 |
Why?
|
| Alleles | 13 | 2023 | 6892 | 0.210 |
Why?
|
| Renin | 1 | 2024 | 648 | 0.200 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 3108 | 0.200 |
Why?
|
| Patient Compliance | 5 | 2018 | 2693 | 0.200 |
Why?
|
| Predictive Value of Tests | 14 | 2019 | 15455 | 0.200 |
Why?
|
| Lipid Metabolism | 3 | 2018 | 1901 | 0.200 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 103 | 0.200 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2019 | 1568 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 86 | 0.190 |
Why?
|
| Reference Values | 6 | 2017 | 4941 | 0.190 |
Why?
|
| Linkage Disequilibrium | 9 | 2021 | 1998 | 0.190 |
Why?
|
| Mental Health | 2 | 2022 | 3276 | 0.190 |
Why?
|
| Sex Distribution | 6 | 2019 | 2281 | 0.190 |
Why?
|
| Telomerase | 3 | 2016 | 752 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 1473 | 0.190 |
Why?
|
| Models, Theoretical | 1 | 2013 | 3579 | 0.190 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2024 | 273 | 0.190 |
Why?
|
| Chromosome Mapping | 4 | 2024 | 4622 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2024 | 224 | 0.190 |
Why?
|
| Receptors, Somatostatin | 2 | 2014 | 138 | 0.190 |
Why?
|
| Telomere | 3 | 2019 | 943 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2016 | 640 | 0.190 |
Why?
|
| Alanine Transaminase | 2 | 2022 | 605 | 0.190 |
Why?
|
| Postmenopause | 6 | 2020 | 2518 | 0.190 |
Why?
|
| Age Distribution | 8 | 2009 | 2877 | 0.180 |
Why?
|
| Gene Frequency | 6 | 2020 | 3617 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 2012 | 276 | 0.180 |
Why?
|
| Genetic Markers | 4 | 2020 | 2604 | 0.180 |
Why?
|
| Pain | 2 | 2006 | 5103 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2016 | 453 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2016 | 4843 | 0.180 |
Why?
|
| Health Services | 1 | 2006 | 756 | 0.180 |
Why?
|
| Ticlopidine | 2 | 2015 | 730 | 0.180 |
Why?
|
| Parkinson Disease | 6 | 2013 | 2895 | 0.180 |
Why?
|
| Simvastatin | 3 | 2011 | 346 | 0.180 |
Why?
|
| Disease Progression | 15 | 2024 | 13646 | 0.180 |
Why?
|
| Estrogen Receptor beta | 3 | 2020 | 171 | 0.180 |
Why?
|
| Carcinoma | 4 | 2016 | 2341 | 0.180 |
Why?
|
| Linoleic Acid | 2 | 2019 | 159 | 0.180 |
Why?
|
| Verbal Behavior | 1 | 2001 | 336 | 0.170 |
Why?
|
| Azithromycin | 1 | 2021 | 200 | 0.170 |
Why?
|
| Longevity | 1 | 2008 | 1077 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2025 | 490 | 0.170 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6318 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 739 | 0.170 |
Why?
|
| Coronary Angiography | 5 | 2025 | 4537 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 4069 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2021 | 313 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2018 | 4142 | 0.170 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2019 | 1724 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 3813 | 0.170 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 1943 | 0.170 |
Why?
|
| Fatty Acids | 4 | 2023 | 1815 | 0.170 |
Why?
|
| Regression Analysis | 10 | 2021 | 6350 | 0.170 |
Why?
|
| Occupational Exposure | 3 | 2024 | 1817 | 0.160 |
Why?
|
| Cataract Extraction | 3 | 2015 | 465 | 0.160 |
Why?
|
| Glycine Hydroxymethyltransferase | 2 | 2012 | 31 | 0.160 |
Why?
|
| Angina Pectoris | 4 | 2016 | 960 | 0.160 |
Why?
|
| Body Weight | 6 | 2018 | 4629 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 5 | 2006 | 2653 | 0.160 |
Why?
|
| Patient Selection | 8 | 2012 | 4266 | 0.160 |
Why?
|
| Patient Admission | 2 | 2019 | 1367 | 0.160 |
Why?
|
| Puerperal Disorders | 1 | 2022 | 303 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2016 | 3464 | 0.160 |
Why?
|
| Leukocytes | 4 | 2020 | 2030 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2020 | 190 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2021 | 244 | 0.160 |
Why?
|
| Life Expectancy | 3 | 2023 | 1249 | 0.160 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2019 | 88 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2016 | 1420 | 0.160 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 20224 | 0.150 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2019 | 279 | 0.150 |
Why?
|
| Receptors, LDL | 4 | 2024 | 491 | 0.150 |
Why?
|
| Drug Combinations | 4 | 2015 | 2079 | 0.150 |
Why?
|
| Sodium, Dietary | 1 | 2022 | 426 | 0.150 |
Why?
|
| Kidney Function Tests | 4 | 2019 | 681 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2010 | 208 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2019 | 191 | 0.150 |
Why?
|
| Parathyroid Hormone | 1 | 2024 | 1804 | 0.150 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 11254 | 0.150 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2023 | 644 | 0.150 |
Why?
|
| Respiratory Aspiration | 2 | 2016 | 89 | 0.150 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 344 | 0.150 |
Why?
|
| Hypertriglyceridemia | 2 | 2007 | 293 | 0.150 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 361 | 0.150 |
Why?
|
| Metabolism | 1 | 2019 | 193 | 0.140 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 429 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 5 | 2015 | 2923 | 0.140 |
Why?
|
| Oleic Acid | 1 | 2017 | 92 | 0.140 |
Why?
|
| Selenomethionine | 2 | 2015 | 18 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 3941 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 5 | 2021 | 1727 | 0.140 |
Why?
|
| Colorectal Neoplasms | 7 | 2018 | 6971 | 0.140 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 187 | 0.140 |
Why?
|
| Uric Acid | 2 | 2022 | 806 | 0.140 |
Why?
|
| Flavonoids | 3 | 2014 | 447 | 0.140 |
Why?
|
| Chromatography, Gas | 2 | 2014 | 150 | 0.140 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 520 | 0.140 |
Why?
|
| Medical Records | 4 | 2013 | 1412 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8634 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 420 | 0.130 |
Why?
|
| Analgesics | 1 | 2003 | 1070 | 0.130 |
Why?
|
| Resistance Training | 1 | 2018 | 199 | 0.130 |
Why?
|
| Tricarboxylic Acids | 1 | 2016 | 26 | 0.130 |
Why?
|
| Hormones | 1 | 2020 | 870 | 0.130 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2019 | 540 | 0.130 |
Why?
|
| Methionine | 2 | 2018 | 573 | 0.130 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2016 | 39 | 0.130 |
Why?
|
| Functional Food | 1 | 2015 | 19 | 0.130 |
Why?
|
| Hospice Care | 1 | 2022 | 679 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 599 | 0.130 |
Why?
|
| Elder Nutritional Physiological Phenomena | 1 | 2015 | 7 | 0.130 |
Why?
|
| Soy Foods | 1 | 2015 | 44 | 0.120 |
Why?
|
| Nitroglycerin | 1 | 2016 | 332 | 0.120 |
Why?
|
| Exercise Test | 1 | 2003 | 2186 | 0.120 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 258 | 0.120 |
Why?
|
| Placebos | 6 | 2010 | 1668 | 0.120 |
Why?
|
| Walking | 2 | 2016 | 1201 | 0.120 |
Why?
|
| Migraine with Aura | 2 | 2008 | 204 | 0.120 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 1337 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 975 | 0.120 |
Why?
|
| Vaccines | 1 | 2023 | 842 | 0.120 |
Why?
|
| Receptors, Leptin | 1 | 2016 | 350 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2018 | 534 | 0.120 |
Why?
|
| Television | 1 | 2018 | 410 | 0.120 |
Why?
|
| Sequence Analysis | 1 | 2015 | 240 | 0.120 |
Why?
|
| Thrombosis | 3 | 2023 | 2955 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 7 | 2023 | 2487 | 0.120 |
Why?
|
| Insulin Resistance | 5 | 2014 | 3981 | 0.120 |
Why?
|
| Australia | 5 | 2018 | 1265 | 0.120 |
Why?
|
| Recovery of Function | 4 | 2022 | 2990 | 0.120 |
Why?
|
| Milk | 3 | 2022 | 443 | 0.120 |
Why?
|
| Brain Neoplasms | 5 | 2013 | 9198 | 0.120 |
Why?
|
| Multifactorial Inheritance | 4 | 2024 | 1421 | 0.120 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2016 | 125 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2020 | 613 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 6541 | 0.110 |
Why?
|
| Survival Analysis | 9 | 2021 | 10117 | 0.110 |
Why?
|
| Muscle Strength | 1 | 2018 | 641 | 0.110 |
Why?
|
| Fibrinolysis | 1 | 2015 | 331 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2015 | 1133 | 0.110 |
Why?
|
| Bariatric Surgery | 1 | 2024 | 1013 | 0.110 |
Why?
|
| Insulin | 7 | 2019 | 6607 | 0.110 |
Why?
|
| Migraine Disorders | 4 | 2019 | 1713 | 0.110 |
Why?
|
| X Chromosome Inactivation | 1 | 2016 | 229 | 0.110 |
Why?
|
| Lipid Peroxides | 1 | 1993 | 74 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2016 | 6409 | 0.110 |
Why?
|
| Breast Neoplasms | 10 | 2010 | 21162 | 0.110 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 806 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 937 | 0.110 |
Why?
|
| Beer | 2 | 2008 | 135 | 0.110 |
Why?
|
| Vitamin B Deficiency | 1 | 2013 | 12 | 0.110 |
Why?
|
| Tryptophan | 3 | 2023 | 482 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2015 | 4859 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 10776 | 0.110 |
Why?
|
| Young Adult | 13 | 2022 | 60049 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2024 | 1462 | 0.110 |
Why?
|
| Aortic Aneurysm | 1 | 2018 | 649 | 0.110 |
Why?
|
| History, 20th Century | 2 | 2012 | 2771 | 0.110 |
Why?
|
| Deglutition | 3 | 2018 | 208 | 0.110 |
Why?
|
| Body Size | 2 | 2014 | 463 | 0.110 |
Why?
|
| Massachusetts | 5 | 2013 | 8902 | 0.110 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 2 | 2020 | 58 | 0.110 |
Why?
|
| Wine | 2 | 2008 | 172 | 0.110 |
Why?
|
| Chemoprevention | 1 | 1996 | 326 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2015 | 425 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2015 | 246 | 0.110 |
Why?
|
| Pacemaker, Artificial | 2 | 2025 | 828 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 4 | 2019 | 2708 | 0.110 |
Why?
|
| Vitamin D Deficiency | 2 | 2024 | 1389 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2005 | 2062 | 0.110 |
Why?
|
| Central Nervous System Depressants | 1 | 2014 | 164 | 0.110 |
Why?
|
| DNA Methylation | 4 | 2016 | 4421 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2023 | 1317 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 13697 | 0.110 |
Why?
|
| Hypersensitivity | 2 | 2013 | 1173 | 0.100 |
Why?
|
| Mental Disorders | 2 | 2019 | 6876 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7463 | 0.100 |
Why?
|
| Pyridoxine | 3 | 2007 | 109 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 684 | 0.100 |
Why?
|
| Iron | 1 | 2021 | 1814 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 849 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 3200 | 0.100 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2012 | 8 | 0.100 |
Why?
|
| Hemorrhage | 3 | 2019 | 3461 | 0.100 |
Why?
|
| Mississippi | 3 | 2018 | 94 | 0.100 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 4303 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2012 | 93 | 0.100 |
Why?
|
| Hemoglobins | 3 | 2022 | 1532 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1997 | 1855 | 0.100 |
Why?
|
| Dairy Products | 3 | 2017 | 490 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2012 | 69 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 3 | 2020 | 581 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 1999 | 985 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2013 | 130 | 0.100 |
Why?
|
| Obesity, Abdominal | 1 | 2015 | 375 | 0.100 |
Why?
|
| Membrane Proteins | 5 | 2022 | 7880 | 0.100 |
Why?
|
| Breast Neoplasms, Male | 1 | 2014 | 212 | 0.100 |
Why?
|
| Mannose-Binding Lectin | 1 | 2013 | 146 | 0.100 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 5375 | 0.100 |
Why?
|
| Asthma | 3 | 2011 | 6280 | 0.100 |
Why?
|
| Copper | 2 | 1993 | 369 | 0.100 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2014 | 268 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2002 | 1959 | 0.100 |
Why?
|
| Energy Intake | 5 | 2021 | 2145 | 0.100 |
Why?
|
| Peripartum Period | 2 | 2023 | 138 | 0.100 |
Why?
|
| Medication Systems | 1 | 2011 | 31 | 0.100 |
Why?
|
| Neopterin | 2 | 2023 | 57 | 0.100 |
Why?
|
| Boston | 9 | 2020 | 9371 | 0.090 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2012 | 193 | 0.090 |
Why?
|
| Health | 1 | 2014 | 399 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 848 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2011 | 81 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1905 | 0.090 |
Why?
|
| ROC Curve | 4 | 2018 | 3623 | 0.090 |
Why?
|
| History, 15th Century | 1 | 2010 | 29 | 0.090 |
Why?
|
| Chromosome Aberrations | 2 | 2015 | 1780 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1126 | 0.090 |
Why?
|
| History, Medieval | 1 | 2010 | 62 | 0.090 |
Why?
|
| Glycine | 1 | 2014 | 672 | 0.090 |
Why?
|
| Endoscopy | 2 | 2018 | 1857 | 0.090 |
Why?
|
| Pharyngeal Diseases | 1 | 2012 | 134 | 0.090 |
Why?
|
| History, 16th Century | 1 | 2010 | 70 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2012 | 220 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 1998 | 2206 | 0.090 |
Why?
|
| Sleep | 3 | 2023 | 4802 | 0.090 |
Why?
|
| Carcinogens | 1 | 2013 | 455 | 0.090 |
Why?
|
| History, 17th Century | 1 | 2010 | 108 | 0.090 |
Why?
|
| Models, Statistical | 3 | 2020 | 5099 | 0.090 |
Why?
|
| Germ-Line Mutation | 3 | 2014 | 1885 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2015 | 797 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2018 | 740 | 0.090 |
Why?
|
| Terminal Care | 1 | 2022 | 1773 | 0.090 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2011 | 122 | 0.090 |
Why?
|
| Esophageal Stenosis | 1 | 2012 | 197 | 0.090 |
Why?
|
| Databases, Genetic | 3 | 2022 | 1748 | 0.090 |
Why?
|
| Nutritional Status | 2 | 2017 | 1627 | 0.090 |
Why?
|
| Sensitivity and Specificity | 8 | 2022 | 14737 | 0.090 |
Why?
|
| Case Management | 1 | 2012 | 276 | 0.090 |
Why?
|
| History, 18th Century | 1 | 2010 | 206 | 0.090 |
Why?
|
| Anemia | 2 | 2010 | 1519 | 0.090 |
Why?
|
| Hematinics | 2 | 2010 | 282 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2012 | 585 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 856 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2024 | 4528 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 1141 | 0.080 |
Why?
|
| Haplotypes | 5 | 2024 | 2724 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2010 | 126 | 0.080 |
Why?
|
| Receptors, Fc | 1 | 2013 | 538 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2011 | 216 | 0.080 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 520 | 0.080 |
Why?
|
| Smoking Cessation | 4 | 2021 | 2083 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2024 | 76 | 0.080 |
Why?
|
| Syncope | 1 | 2012 | 430 | 0.080 |
Why?
|
| Neuropsychological Tests | 5 | 2019 | 7145 | 0.080 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Xanthophylls | 4 | 2008 | 95 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 192 | 0.080 |
Why?
|
| Gastric Fistula | 1 | 1990 | 73 | 0.080 |
Why?
|
| Demography | 2 | 2012 | 1642 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 1990 | 144 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 2587 | 0.080 |
Why?
|
| Aromatase | 1 | 2009 | 147 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 2258 | 0.080 |
Why?
|
| Lipase | 2 | 2022 | 321 | 0.080 |
Why?
|
| Pleural Diseases | 1 | 1990 | 138 | 0.080 |
Why?
|
| Apolipoproteins | 3 | 2023 | 328 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2012 | 2663 | 0.080 |
Why?
|
| Endostatins | 1 | 2009 | 168 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2012 | 891 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2004 | 3777 | 0.080 |
Why?
|
| Animals | 22 | 2024 | 169337 | 0.080 |
Why?
|
| Sample Size | 2 | 2010 | 848 | 0.080 |
Why?
|
| Subarachnoid Hemorrhage | 3 | 2014 | 1039 | 0.080 |
Why?
|
| Research Personnel | 1 | 2013 | 590 | 0.080 |
Why?
|
| Calcium | 4 | 2022 | 5794 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 2 | 2011 | 713 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 1652 | 0.080 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2008 | 6 | 0.080 |
Why?
|
| Calcium, Dietary | 2 | 2001 | 533 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 1498 | 0.080 |
Why?
|
| Endothelium, Vascular | 5 | 2011 | 4427 | 0.080 |
Why?
|
| Morbidity | 2 | 2007 | 1758 | 0.080 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 1753 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 1990 | 203 | 0.080 |
Why?
|
| Quadriplegia | 1 | 1990 | 227 | 0.080 |
Why?
|
| Leptin | 1 | 2016 | 1597 | 0.080 |
Why?
|
| Fistula | 1 | 1990 | 213 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 277 | 0.080 |
Why?
|
| Health Status Indicators | 3 | 2009 | 971 | 0.080 |
Why?
|
| Causality | 2 | 2012 | 1255 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2010 | 715 | 0.080 |
Why?
|
| Periodicals as Topic | 2 | 2011 | 1469 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 3407 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1813 | 0.070 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 28 | 0.070 |
Why?
|
| Resistin | 1 | 2008 | 172 | 0.070 |
Why?
|
| New England | 1 | 2011 | 1058 | 0.070 |
Why?
|
| Recurrence | 4 | 2016 | 8506 | 0.070 |
Why?
|
| American Heart Association | 1 | 2012 | 1051 | 0.070 |
Why?
|
| Fragaria | 1 | 2007 | 21 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2024 | 8731 | 0.070 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2007 | 99 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2014 | 113 | 0.070 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 1736 | 0.070 |
Why?
|
| Attitude to Health | 2 | 2014 | 2025 | 0.070 |
Why?
|
| Fibrinolytic Agents | 3 | 2005 | 2074 | 0.070 |
Why?
|
| Poultry | 2 | 2024 | 79 | 0.070 |
Why?
|
| Adolescent | 11 | 2019 | 89184 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2017 | 1252 | 0.070 |
Why?
|
| Lipid Peroxidation | 3 | 1998 | 276 | 0.070 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 332 | 0.070 |
Why?
|
| Fluoroscopy | 4 | 2016 | 952 | 0.070 |
Why?
|
| Food Handling | 1 | 2007 | 158 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2021 | 23631 | 0.070 |
Why?
|
| Sex Characteristics | 5 | 2022 | 2660 | 0.070 |
Why?
|
| Receptors, Androgen | 2 | 2010 | 1083 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 930 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 56 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3610 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2014 | 1539 | 0.070 |
Why?
|
| Genome, Human | 2 | 2021 | 4450 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1575 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 213 | 0.070 |
Why?
|
| Data Collection | 1 | 2015 | 3324 | 0.070 |
Why?
|
| Adiposity | 4 | 2019 | 1895 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 1597 | 0.070 |
Why?
|
| Cystatin C | 1 | 2007 | 272 | 0.070 |
Why?
|
| Carbonated Beverages | 1 | 2007 | 210 | 0.070 |
Why?
|
| Health Promotion | 1 | 1998 | 2209 | 0.060 |
Why?
|
| Databases, Factual | 6 | 2021 | 8075 | 0.060 |
Why?
|
| Cholesterol Esters | 2 | 1997 | 72 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2024 | 4819 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 899 | 0.060 |
Why?
|
| Phosphorus | 1 | 2007 | 336 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 2 | 2021 | 1004 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 1309 | 0.060 |
Why?
|
| Asia | 2 | 2018 | 627 | 0.060 |
Why?
|
| Quality of Life | 3 | 2016 | 13503 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 299 | 0.060 |
Why?
|
| Medical Order Entry Systems | 1 | 2011 | 523 | 0.060 |
Why?
|
| Oxidation-Reduction | 3 | 1999 | 2225 | 0.060 |
Why?
|
| Quality Control | 2 | 2020 | 833 | 0.060 |
Why?
|
| Migraine without Aura | 1 | 2006 | 82 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2004 | 2106 | 0.060 |
Why?
|
| Organ Specificity | 2 | 2021 | 1967 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2442 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 887 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2008 | 401 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 6085 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 489 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 3827 | 0.060 |
Why?
|
| Proteins | 2 | 2024 | 6006 | 0.060 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 1506 | 0.060 |
Why?
|
| Propensity Score | 3 | 2020 | 1962 | 0.060 |
Why?
|
| Food, Fortified | 2 | 1996 | 189 | 0.060 |
Why?
|
| Sick Sinus Syndrome | 1 | 2025 | 51 | 0.060 |
Why?
|
| Chemical Warfare Agents | 1 | 2024 | 19 | 0.060 |
Why?
|
| Metformin | 1 | 2012 | 911 | 0.060 |
Why?
|
| Defoliants, Chemical | 1 | 2024 | 9 | 0.060 |
Why?
|
| Weight Gain | 1 | 2015 | 2356 | 0.060 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2024 | 15 | 0.060 |
Why?
|
| Likelihood Functions | 2 | 2008 | 993 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2007 | 4039 | 0.060 |
Why?
|
| Ibuprofen | 1 | 2006 | 229 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 2952 | 0.060 |
Why?
|
| Gene Expression | 3 | 2024 | 7598 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 2482 | 0.060 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 2024 | 25 | 0.060 |
Why?
|
| Complement Factor H | 1 | 2024 | 110 | 0.060 |
Why?
|
| Myocardial Revascularization | 3 | 2007 | 796 | 0.060 |
Why?
|
| Hydrotherapy | 1 | 2003 | 6 | 0.060 |
Why?
|
| Cerebral Arteries | 2 | 2005 | 489 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3666 | 0.060 |
Why?
|
| Health Policy | 1 | 2016 | 2698 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 321 | 0.060 |
Why?
|
| Penetrance | 1 | 2005 | 384 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2005 | 370 | 0.060 |
Why?
|
| Systole | 2 | 2009 | 937 | 0.060 |
Why?
|
| Allergens | 1 | 2011 | 1441 | 0.060 |
Why?
|
| Knowledge Bases | 1 | 2024 | 97 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2019 | 1642 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 623 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 3236 | 0.050 |
Why?
|
| Hyperhomocysteinemia | 1 | 2004 | 118 | 0.050 |
Why?
|
| Stents | 1 | 2015 | 3201 | 0.050 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2024 | 148 | 0.050 |
Why?
|
| Leg | 1 | 2008 | 1088 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2010 | 1309 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2003 | 125 | 0.050 |
Why?
|
| Afghan Campaign 2001- | 1 | 2024 | 298 | 0.050 |
Why?
|
| Hospitals, Veterans | 2 | 2004 | 395 | 0.050 |
Why?
|
| Xerostomia | 1 | 2003 | 94 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2003 | 278 | 0.050 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2008 | 577 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1825 | 0.050 |
Why?
|
| Logical Observation Identifiers Names and Codes | 1 | 2022 | 16 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2010 | 2204 | 0.050 |
Why?
|
| Heterozygote | 3 | 2018 | 2791 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2412 | 0.050 |
Why?
|
| Laminin | 1 | 2024 | 406 | 0.050 |
Why?
|
| Streptokinase | 2 | 2000 | 186 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2010 | 1802 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2005 | 595 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 2360 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2011 | 1238 | 0.050 |
Why?
|
| Research Support as Topic | 1 | 2006 | 696 | 0.050 |
Why?
|
| Mucin-5B | 1 | 2022 | 148 | 0.050 |
Why?
|
| Mass Screening | 4 | 2012 | 5451 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2337 | 0.050 |
Why?
|
| Voice Quality | 1 | 2003 | 226 | 0.050 |
Why?
|
| Pesticides | 1 | 2024 | 299 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2003 | 245 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 20765 | 0.050 |
Why?
|
| Editorial Policies | 1 | 2006 | 459 | 0.050 |
Why?
|
| Allylamine | 1 | 2001 | 10 | 0.050 |
Why?
|
| Type A Personality | 1 | 2001 | 24 | 0.050 |
Why?
|
| Speech Production Measurement | 1 | 2001 | 99 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 1434 | 0.050 |
Why?
|
| Lutein | 3 | 2008 | 123 | 0.050 |
Why?
|
| Genetic Pleiotropy | 1 | 2022 | 181 | 0.050 |
Why?
|
| Cyclin T | 1 | 2021 | 19 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2003 | 411 | 0.050 |
Why?
|
| Interleukin-10 Receptor beta Subunit | 1 | 2021 | 16 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2006 | 555 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2010 | 873 | 0.050 |
Why?
|
| Tea | 2 | 2003 | 289 | 0.050 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2023 | 210 | 0.050 |
Why?
|
| Interviews as Topic | 3 | 2010 | 2740 | 0.050 |
Why?
|
| Diastole | 2 | 2000 | 784 | 0.050 |
Why?
|
| GATA5 Transcription Factor | 1 | 2020 | 18 | 0.050 |
Why?
|
| Drug Costs | 2 | 2000 | 1196 | 0.050 |
Why?
|
| Yogurt | 1 | 2021 | 71 | 0.050 |
Why?
|
| Phospholipase C beta | 1 | 2020 | 49 | 0.050 |
Why?
|
| Pedigree | 1 | 2008 | 4544 | 0.050 |
Why?
|
| Tunica Media | 1 | 2001 | 111 | 0.050 |
Why?
|
| Lysophospholipase | 1 | 2020 | 66 | 0.040 |
Why?
|
| Population Groups | 1 | 2021 | 208 | 0.040 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2021 | 113 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 3438 | 0.040 |
Why?
|
| Heart Rate | 1 | 2012 | 4218 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 876 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2011 | 1925 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2003 | 366 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 3 | 1997 | 1486 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 1209 | 0.040 |
Why?
|
| 4-Quinolones | 1 | 1999 | 25 | 0.040 |
Why?
|
| Computational Biology | 3 | 2019 | 3543 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 2433 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2022 | 383 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 1997 | 1894 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 185 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2024 | 634 | 0.040 |
Why?
|
| Portugal | 1 | 2020 | 91 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1585 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2003 | 417 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1163 | 0.040 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2019 | 50 | 0.040 |
Why?
|
| Gemfibrozil | 1 | 1999 | 30 | 0.040 |
Why?
|
| Tetracyclines | 1 | 1999 | 64 | 0.040 |
Why?
|
| Liver | 3 | 2020 | 7574 | 0.040 |
Why?
|
| Counseling | 2 | 2014 | 1553 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2012 | 300 | 0.040 |
Why?
|
| Diet, Atherogenic | 2 | 1996 | 92 | 0.040 |
Why?
|
| Unified Medical Language System | 1 | 2019 | 89 | 0.040 |
Why?
|
| Pyridoxic Acid | 1 | 2019 | 4 | 0.040 |
Why?
|
| Uromodulin | 1 | 2019 | 48 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5422 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2060 | 0.040 |
Why?
|
| Thrombolytic Therapy | 2 | 2000 | 2050 | 0.040 |
Why?
|
| DNA | 2 | 2013 | 7211 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2019 | 127 | 0.040 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2019 | 121 | 0.040 |
Why?
|
| Time | 1 | 2001 | 546 | 0.040 |
Why?
|
| Drug-Eluting Stents | 2 | 2015 | 681 | 0.040 |
Why?
|
| Ampulla of Vater | 1 | 2019 | 150 | 0.040 |
Why?
|
| Diuretics | 1 | 2022 | 612 | 0.040 |
Why?
|
| Bile Ducts | 1 | 2020 | 288 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2004 | 3476 | 0.040 |
Why?
|
| Tunica Intima | 1 | 2001 | 459 | 0.040 |
Why?
|
| NAD | 1 | 2023 | 618 | 0.040 |
Why?
|
| Factor V | 1 | 2019 | 168 | 0.040 |
Why?
|
| Gene Expression Regulation | 3 | 2021 | 11918 | 0.040 |
Why?
|
| Ion Channels | 1 | 2023 | 1044 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2019 | 174 | 0.040 |
Why?
|
| Nutrition Assessment | 2 | 2015 | 740 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2024 | 3587 | 0.040 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2020 | 179 | 0.040 |
Why?
|
| Medicare | 3 | 2023 | 6881 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 144 | 0.040 |
Why?
|
| Pharmacoepidemiology | 1 | 2021 | 351 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2022 | 6277 | 0.040 |
Why?
|
| Mutation, Missense | 2 | 2023 | 2593 | 0.040 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3801 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 412 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2018 | 101 | 0.040 |
Why?
|
| Patient Participation | 1 | 2007 | 1448 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 1318 | 0.040 |
Why?
|
| Self-Injurious Behavior | 1 | 2024 | 568 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2003 | 493 | 0.040 |
Why?
|
| Pancreatitis, Chronic | 1 | 2020 | 282 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 2 | 2000 | 1364 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1994 | 1493 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2000 | 250 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 1999 | 414 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2010 | 4936 | 0.040 |
Why?
|
| Caffeine | 2 | 2015 | 702 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 3243 | 0.040 |
Why?
|
| Length of Stay | 1 | 2011 | 6519 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 1459 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2018 | 386 | 0.030 |
Why?
|
| Nutrition Policy | 1 | 2001 | 467 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1999 | 685 | 0.030 |
Why?
|
| China | 2 | 2013 | 2395 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 1996 | 62 | 0.030 |
Why?
|
| Kidney Tubules | 1 | 2018 | 448 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2023 | 3164 | 0.030 |
Why?
|
| Video Recording | 2 | 2015 | 974 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2020 | 683 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1997 | 313 | 0.030 |
Why?
|
| Aconitic Acid | 1 | 2016 | 13 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 4775 | 0.030 |
Why?
|
| Death, Sudden | 1 | 2018 | 301 | 0.030 |
Why?
|
| Public Health | 2 | 2023 | 2682 | 0.030 |
Why?
|
| Isocitrates | 1 | 2016 | 23 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 8051 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 2020 | 554 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2015 | 6241 | 0.030 |
Why?
|
| Telephone | 2 | 2012 | 630 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2017 | 275 | 0.030 |
Why?
|
| Nutritive Value | 1 | 2019 | 351 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2022 | 998 | 0.030 |
Why?
|
| Veterans Disability Claims | 1 | 2015 | 24 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2023 | 1965 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 864 | 0.030 |
Why?
|
| Weight Loss | 1 | 2007 | 2713 | 0.030 |
Why?
|
| Collagen | 1 | 2024 | 2646 | 0.030 |
Why?
|
| MEDLINE | 1 | 2015 | 119 | 0.030 |
Why?
|
| Oils | 1 | 2015 | 55 | 0.030 |
Why?
|
| Syndrome | 1 | 2022 | 3275 | 0.030 |
Why?
|
| Soybean Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| Spirometry | 1 | 2018 | 928 | 0.030 |
Why?
|
| Barium Sulfate | 1 | 2015 | 180 | 0.030 |
Why?
|
| Mental Recall | 1 | 2001 | 1226 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2022 | 1990 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 17135 | 0.030 |
Why?
|
| Models, Biological | 2 | 2009 | 9493 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1996 | 564 | 0.030 |
Why?
|
| Hospital Mortality | 2 | 2007 | 5367 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2001 | 1428 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2024 | 1409 | 0.030 |
Why?
|
| Dinoprost | 1 | 1995 | 139 | 0.030 |
Why?
|
| Particle Size | 1 | 1999 | 1653 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2020 | 864 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 2429 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2016 | 248 | 0.030 |
Why?
|
| Isoflavones | 1 | 2015 | 139 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1997 | 597 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 1995 | 296 | 0.030 |
Why?
|
| Calcinosis | 1 | 2003 | 1481 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 941 | 0.030 |
Why?
|
| Biological Availability | 1 | 1995 | 392 | 0.030 |
Why?
|
| Aortography | 1 | 2016 | 422 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1995 | 612 | 0.030 |
Why?
|
| Abdomen | 1 | 2020 | 1136 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2015 | 204 | 0.030 |
Why?
|
| Drinking | 1 | 2015 | 197 | 0.030 |
Why?
|
| Epididymitis | 1 | 2014 | 37 | 0.030 |
Why?
|
| Food | 1 | 2019 | 768 | 0.030 |
Why?
|
| Orchitis | 1 | 2014 | 36 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 88 | 0.030 |
Why?
|
| Intestinal Absorption | 1 | 1995 | 400 | 0.030 |
Why?
|
| Registries | 3 | 2020 | 8379 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8562 | 0.030 |
Why?
|
| Klinefelter Syndrome | 1 | 2014 | 48 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 551 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2014 | 369 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 1993 | 138 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1993 | 209 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2000 | 1191 | 0.030 |
Why?
|
| Peroxides | 1 | 1993 | 76 | 0.030 |
Why?
|
| Urban Population | 1 | 2001 | 2045 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2018 | 942 | 0.030 |
Why?
|
| Gynecomastia | 1 | 2014 | 88 | 0.030 |
Why?
|
| Laboratories | 1 | 2017 | 463 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 1053 | 0.030 |
Why?
|
| Oxidants | 1 | 1993 | 168 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 1751 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2015 | 241 | 0.030 |
Why?
|
| Proinsulin | 1 | 2013 | 135 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 601 | 0.030 |
Why?
|
| Steroid Hydroxylases | 1 | 2013 | 93 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2015 | 3960 | 0.030 |
Why?
|
| Suicide | 1 | 2024 | 1607 | 0.030 |
Why?
|
| Thymidylate Synthase | 1 | 2012 | 74 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2013 | 149 | 0.030 |
Why?
|
| Ubiquinone | 1 | 1993 | 183 | 0.030 |
Why?
|
| Sarcosine Dehydrogenase | 1 | 2011 | 5 | 0.020 |
Why?
|
| Formate-Tetrahydrofolate Ligase | 1 | 2011 | 5 | 0.020 |
Why?
|
| Celiac Disease | 1 | 2020 | 820 | 0.020 |
Why?
|
| Aminohydrolases | 1 | 2011 | 18 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1993 | 343 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2011 | 18 | 0.020 |
Why?
|
| Trace Elements | 1 | 2013 | 193 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 746 | 0.020 |
Why?
|
| Amplified Fragment Length Polymorphism Analysis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2008 | 5538 | 0.020 |
Why?
|
| Menopause | 1 | 2020 | 1653 | 0.020 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 417 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2890 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2015 | 594 | 0.020 |
Why?
|
| Homozygote | 2 | 2011 | 1779 | 0.020 |
Why?
|
| Health Personnel | 3 | 2014 | 3380 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 222 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2013 | 173 | 0.020 |
Why?
|
| Flavonols | 1 | 2011 | 85 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1608 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2020 | 2574 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2001 | 1593 | 0.020 |
Why?
|
| France | 1 | 2012 | 497 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2862 | 0.020 |
Why?
|
| Alu Elements | 1 | 2011 | 116 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2012 | 163 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 3794 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 969 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2565 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2015 | 632 | 0.020 |
Why?
|
| Sweden | 1 | 2014 | 1383 | 0.020 |
Why?
|
| Mice | 4 | 2019 | 82017 | 0.020 |
Why?
|
| Population Surveillance | 2 | 2018 | 2598 | 0.020 |
Why?
|
| Metals | 1 | 2015 | 713 | 0.020 |
Why?
|
| Pregnancy | 2 | 2023 | 30200 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3211 | 0.020 |
Why?
|
| Biological Transport | 1 | 1995 | 2085 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2968 | 0.020 |
Why?
|
| Dilatation | 1 | 2012 | 313 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 793 | 0.020 |
Why?
|
| Testis | 1 | 2014 | 783 | 0.020 |
Why?
|
| Aorta, Thoracic | 2 | 1994 | 1112 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 616 | 0.020 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 711 | 0.020 |
Why?
|
| Aorta | 1 | 1998 | 2046 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 4570 | 0.020 |
Why?
|
| Israel | 1 | 2012 | 726 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3431 | 0.020 |
Why?
|
| Iron Compounds | 1 | 2010 | 28 | 0.020 |
Why?
|
| Glycosyltransferases | 1 | 2010 | 114 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2016 | 741 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2911 | 0.020 |
Why?
|
| Fats | 1 | 2010 | 99 | 0.020 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 1515 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2533 | 0.020 |
Why?
|
| Vasodilation | 1 | 1994 | 968 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 332 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2010 | 148 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2020 | 2986 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 911 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 948 | 0.020 |
Why?
|
| Proteomics | 1 | 2023 | 3906 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 862 | 0.020 |
Why?
|
| Reproduction | 1 | 2014 | 646 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2022 | 5151 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 478 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2010 | 257 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 805 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1545 | 0.020 |
Why?
|
| Depression | 2 | 2024 | 8241 | 0.020 |
Why?
|
| Contrast Media | 2 | 2015 | 5336 | 0.020 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2009 | 74 | 0.020 |
Why?
|
| Acute Disease | 1 | 2000 | 7242 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2015 | 1440 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 348 | 0.020 |
Why?
|
| Observation | 1 | 2010 | 311 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1480 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 351 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 22355 | 0.020 |
Why?
|
| Heart | 1 | 2022 | 4449 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 1995 | 1397 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 1990 | 222 | 0.020 |
Why?
|
| Glioblastoma | 2 | 2015 | 3526 | 0.020 |
Why?
|
| Rabbits | 4 | 1996 | 4781 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2000 | 3139 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2011 | 769 | 0.020 |
Why?
|
| Heme | 1 | 2010 | 316 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2011 | 665 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2015 | 2126 | 0.020 |
Why?
|
| Fish Oils | 1 | 2012 | 483 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 4526 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 1929 | 0.020 |
Why?
|
| Reoperation | 1 | 2018 | 4341 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2020 | 2293 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 494 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 534 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 1567 | 0.020 |
Why?
|
| Dietary Fiber | 1 | 2011 | 767 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 3643 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1309 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2012 | 853 | 0.020 |
Why?
|
| Sucrose | 1 | 2007 | 159 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 410 | 0.020 |
Why?
|
| Self Care | 1 | 2012 | 797 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2016 | 4291 | 0.020 |
Why?
|
| Child | 2 | 2010 | 80891 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 9510 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 968 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 1088 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 5496 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2009 | 501 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1766 | 0.020 |
Why?
|
| Climate | 1 | 2007 | 147 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2007 | 767 | 0.020 |
Why?
|
| Pneumonia | 1 | 2018 | 2163 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3581 | 0.020 |
Why?
|
| Calcifediol | 1 | 2007 | 160 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11854 | 0.020 |
Why?
|
| Nurses | 1 | 2016 | 2494 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 984 | 0.020 |
Why?
|
| Self Medication | 1 | 2006 | 115 | 0.020 |
Why?
|
| Histones | 1 | 2016 | 2592 | 0.020 |
Why?
|
| Lipoproteins | 3 | 1996 | 880 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2011 | 1617 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 1010 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3858 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 1428 | 0.020 |
Why?
|
| Calcitriol | 1 | 2007 | 303 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15597 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2019 | 3312 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3413 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2011 | 1020 | 0.020 |
Why?
|
| Death Certificates | 1 | 2006 | 175 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2009 | 603 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2021 | 4748 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1994 | 2144 | 0.010 |
Why?
|
| Sweetening Agents | 1 | 2007 | 290 | 0.010 |
Why?
|
| Albumins | 1 | 2007 | 577 | 0.010 |
Why?
|
| Environment | 1 | 2011 | 1124 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2024 | 12166 | 0.010 |
Why?
|
| Echocardiography | 1 | 2017 | 5044 | 0.010 |
Why?
|
| Selection Bias | 1 | 2006 | 360 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1996 | 3078 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2015 | 1643 | 0.010 |
Why?
|
| Calcimycin | 2 | 1994 | 214 | 0.010 |
Why?
|
| Research | 2 | 2004 | 1981 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 2003 | 29 | 0.010 |
Why?
|
| Puerto Rico | 1 | 2005 | 380 | 0.010 |
Why?
|
| Brassica | 1 | 2003 | 39 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2007 | 1605 | 0.010 |
Why?
|
| Germany | 1 | 2005 | 882 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2011 | 1841 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 579 | 0.010 |
Why?
|
| Cytokines | 1 | 1998 | 7445 | 0.010 |
Why?
|
| Malus | 1 | 2003 | 51 | 0.010 |
Why?
|
| Cost Savings | 1 | 2008 | 915 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2257 | 0.010 |
Why?
|
| Decision Making | 1 | 2016 | 3953 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 19022 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3442 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1813 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2002 | 113 | 0.010 |
Why?
|
| Angioplasty | 1 | 2004 | 357 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1748 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1994 | 629 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 2392 | 0.010 |
Why?
|
| Cholagogues and Choleretics | 1 | 2001 | 39 | 0.010 |
Why?
|
| Proteinuria | 1 | 2004 | 613 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7861 | 0.010 |
Why?
|
| Genome | 1 | 2009 | 1747 | 0.010 |
Why?
|
| Seasons | 1 | 2007 | 1526 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 1502 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2001 | 286 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2021 | 26411 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 1515 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 10267 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1509 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 3486 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2010 | 3131 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2139 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 187 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14481 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 18362 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2002 | 515 | 0.010 |
Why?
|
| Mutation | 2 | 2020 | 30228 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 1794 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 2139 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 1997 | 64 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2000 | 15881 | 0.010 |
Why?
|
| Capsules | 1 | 1997 | 193 | 0.010 |
Why?
|
| Anistreplase | 1 | 1996 | 11 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2635 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 3633 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2728 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2002 | 597 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2181 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1997 | 491 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 3520 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1684 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2003 | 2922 | 0.010 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2004 | 982 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1998 | 577 | 0.010 |
Why?
|
| Premedication | 1 | 1996 | 246 | 0.010 |
Why?
|
| Nitrates | 1 | 1996 | 260 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 11120 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 3267 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1996 | 687 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 1309 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1998 | 910 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1994 | 272 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1996 | 692 | 0.010 |
Why?
|
| Methylation | 1 | 1996 | 1076 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 9433 | 0.010 |
Why?
|
| Magnesium | 1 | 1996 | 816 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1996 | 1153 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 775 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1994 | 946 | 0.010 |
Why?
|
| Femoral Artery | 1 | 1996 | 829 | 0.010 |
Why?
|
| Arteries | 1 | 1997 | 1126 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1997 | 1561 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1996 | 835 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 1244 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1996 | 1517 | 0.010 |
Why?
|
| Veins | 1 | 1994 | 768 | 0.010 |
Why?
|
| Heparin | 1 | 1996 | 1636 | 0.010 |
Why?
|
| Melanoma | 1 | 2007 | 5705 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 3553 | 0.000 |
Why?
|
| Radiography | 1 | 1996 | 6993 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1991 | 2363 | 0.000 |
Why?
|
| Brain | 1 | 2005 | 27454 | 0.000 |
Why?
|